Does EDOXABAN TOSILATE Cause Interstitial lung disease? 8 Reports in FDA Database
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
According to the FDA Adverse Event Reporting System (FAERS), 8 reports of Interstitial lung disease have been filed in association with EDOXABAN TOSILATE. This represents 2.1% of all adverse event reports for EDOXABAN TOSILATE.
8
Reports of Interstitial lung disease with EDOXABAN TOSILATE
2.1%
of all EDOXABAN TOSILATE reports
3
Deaths
7
Hospitalizations
How Dangerous Is Interstitial lung disease From EDOXABAN TOSILATE?
Of the 8 reports, 3 (37.5%) resulted in death, 7 (87.5%) required hospitalization, and 1 (12.5%) were considered life-threatening.
Is Interstitial lung disease Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for EDOXABAN TOSILATE. However, 8 reports have been filed with the FAERS database.
What Other Side Effects Does EDOXABAN TOSILATE Cause?
Cerebral infarction (44)
Anaemia (15)
Embolic stroke (14)
Off label use (14)
Cerebrovascular accident (12)
Epistaxis (11)
Pulmonary embolism (11)
Gastrointestinal haemorrhage (10)
Cerebral haemorrhage (9)
Death (9)
What Other Drugs Cause Interstitial lung disease?
METHOTREXATE (3,049)
RITUXIMAB (2,458)
PEMBROLIZUMAB (2,113)
PREDNISONE (1,850)
CYCLOPHOSPHAMIDE (1,725)
NIVOLUMAB (1,538)
AMIODARONE (1,421)
DOXORUBICIN (1,352)
ETANERCEPT (1,267)
ADALIMUMAB (1,250)
Which EDOXABAN TOSILATE Alternatives Have Lower Interstitial lung disease Risk?
EDOXABAN TOSILATE vs EFALIZUMAB
EDOXABAN TOSILATE vs EFANESOCTOCOG ALFA
EDOXABAN TOSILATE vs EFAVIRENZ
EDOXABAN TOSILATE vs EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL
EDOXABAN TOSILATE vs EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL